BioPharma Credit PLC (FRA:B3P)
Germany
· Delayed Price · Currency is EUR 0.780
0.00 (0.00%)
At close: Dec 4, 2025
BioPharma Credit Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2017 |
| Other Revenue | 154.66 | 150.03 | 135.74 | 218.17 | 103.88 | 110.02 | Upgrade
|
| Revenue | 154.66 | 150.03 | 135.74 | 218.17 | 103.88 | 110.02 | Upgrade
|
| Revenue Growth (YoY) | 13.42% | 10.53% | -37.78% | 110.02% | -5.58% | -27.09% | Upgrade
|
| Gross Profit | 154.66 | 150.03 | 135.74 | 218.17 | 103.88 | 110.02 | Upgrade
|
| Selling, General & Admin | 31.65 | 27.72 | 27.28 | 35.79 | 18.95 | 20.87 | Upgrade
|
| Other Operating Expenses | -0.08 | 0.13 | 0 | 0.04 | -0.05 | - | Upgrade
|
| Operating Expenses | 31.56 | 27.85 | 27.28 | 35.83 | 18.9 | 20.87 | Upgrade
|
| Operating Income | 123.1 | 122.18 | 108.46 | 182.34 | 84.98 | 89.15 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.02 | -0 | -0.01 | -0.03 | -0.02 | -0.01 | Upgrade
|
| Pretax Income | 123.12 | 122.18 | 108.45 | 182.31 | 84.96 | 89.14 | Upgrade
|
| Net Income | 123.12 | 122.18 | 108.45 | 182.31 | 84.96 | 89.14 | Upgrade
|
| Net Income to Common | 123.12 | 122.18 | 108.45 | 182.31 | 84.96 | 89.14 | Upgrade
|
| Net Income Growth | 12.58% | 12.66% | -40.51% | 114.59% | -4.69% | -27.13% | Upgrade
|
| Shares Outstanding (Basic) | 1,174 | 1,222 | 1,309 | 1,364 | 1,374 | 1,374 | Upgrade
|
| Shares Outstanding (Diluted) | 1,174 | 1,222 | 1,309 | 1,364 | 1,374 | 1,374 | Upgrade
|
| Shares Change (YoY) | -7.85% | -6.65% | -4.00% | -0.72% | -0.00% | -0.00% | Upgrade
|
| EPS (Basic) | 0.10 | 0.10 | 0.08 | 0.13 | 0.06 | 0.06 | Upgrade
|
| EPS (Diluted) | 0.10 | 0.10 | 0.08 | 0.13 | 0.06 | 0.06 | Upgrade
|
| EPS Growth | 22.17% | 20.68% | -38.03% | 116.14% | -4.68% | -27.13% | Upgrade
|
| Dividend Per Share | 0.070 | 0.070 | 0.070 | 0.070 | 0.070 | 0.070 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | 79.59% | 81.44% | 79.90% | 83.58% | 81.80% | 81.03% | Upgrade
|
| Profit Margin | 79.61% | 81.44% | 79.90% | 83.56% | 81.79% | 81.02% | Upgrade
|
| EBIT | 123.1 | 122.18 | 108.46 | 182.34 | 84.98 | 89.15 | Upgrade
|
| EBIT Margin | 79.59% | 81.44% | 79.90% | 83.58% | 81.80% | 81.03% | Upgrade
|
| Revenue as Reported | 154.69 | 150.03 | 135.73 | 218.14 | 103.86 | 110.01 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.